Praxis Precision Medicines is rated a Strong Buy due to two pending New Drug Applications (NDAs) and promising pipeline expansions targeting essential tremor and developmental and epileptic encephalopathies. Their drug relutrigine showed a 46% reduction in motor seizures for specific epileptic conditions and is under FDA priority review with a decision expected by September 27, 2026. The company also plans to expand relutrigine's use and develop elsunersen for early-onset SCN2A DEE, with important data expected in 2026–2027. With nearly $1.5 billion in cash raised by early 2026, Praxis is well-funded through 2028 to support research and regulatory milestones.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Ethereum (ETH) has outperformed Bitcoin (BTC) in Q3, driven by a rally sparked by a softer CPI report and strong on-chain metrics. The recent surge pushed ETH above $1,900, triggering significant liquidations in futures positions. However, ETH now fa...
Solana's number of wallets holding tokenized real-world assets (RWAs) has exceeded 300,000, surpassing Ethereum's roughly 200,000 holders. While Solana's RWA value doubled in 2026 to $3.45 billion, Ethereum still leads with $16.3 billion in tokenized...
Baidu's board has approved a plan to convert to a dual-primary listing on the Hong Kong Stock Exchange's Main Board, alongside its existing Nasdaq listing. This move aims to enhance the liquidity of Baidu's shares, broaden its investor base, and prov...
